Ambrx Biopharma Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ambrx Biopharma Inc 's ROA in the third quarter of 2023?
Ambrx Biopharma Inc recorded a cumulative net loss of $-134 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -70.49%.

However, within the Healthcare sector 747 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 4595, from total ROA ranking in the second quarter of 2023 at 4735.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter
Y / Y Total Assets Change	94.24 %	32.2 %	-25.15 %	-65.63 %	-40.52 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-134	-127	-138	-145	-135
Return On Assets (TTM)	-70.49 %	-80.11 %	-96.23 %	-92.1 %	-69.55 %
AMAM's Total Ranking	# 4595	# 4735	# 4978	# 5759	#
Total Assets (TTM) in million	265	247	171	78	136
Seq. Total Assets Change	7.02 %	44.24 %	120.55 %	-42.94 %	-27.17 %
Seq. Net Income Change	-	-	-	-	-

AMAM's 5 Years Annual ROA >> Back to AMAM Management Effectiveness >> Compare AMAM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 119
Sector	# 748
Overall	# 4511

Return On Assets Statistics
High	Average	Low
-29.82 %	-59.27 %	-73.83 %
(Dec 31 2021)		(Dec 31 2022)

Financial Statements
Ambrx Biopharma Inc 's Assets	$ 265 million	AMAM's Balance sheet
Ambrx Biopharma Inc 's Income	$ -23 million	Quarterly AMAM's Income Statement
AMAM's Income by Division		See AMAM's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY	FY
Y / Y Total Assets Change	-56.28 %	-	-	-	-
Total Assets in million	78	178	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-78	-68	0	0	0
Annual Return On Assets	-100.35 %	-38.41 %	-	-	-

AMAM's 5 Years Annual ROA >> Back to AMAM Management Effectiveness >> Compare AMAM ROA to its Competitors

More Return On Assets Ratios
AMAM's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMAM's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMAM's Competitors
Subscribers only: Roa for Ambrx Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for AMAM's Customers

You may also want to know
AMAM's Roi	AMAM's Inventory Turnover Ratio	AMAM's Growth Rates	AMAM's Dividend Comparisons
	AMAM's Profitability Ratios	AMAM's Asset Turnover Ratio	AMAM's Dividend Growth
AMAM's Roe	AMAM's Valuation Ratios	AMAM's Financial Strength Ratios	AMAM's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.